Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil Minoxidil 4/27/2026
Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Anyone tried Anagen “Smooth Release” oral minoxidil?
People are discussing Anagen's "Smooth Release" oral minoxidil, with some users reporting no side effects or hair growth yet. There are concerns about a potential lawsuit with Veradermics over intellectual property, but no confirmed legal action has been found.
community I’m taking Veradermics VDPHL01 - AMA
A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.
community How Veradermics secured a total of $220 million in series B and C financing for oral minoxidil, I will never understand.....
Veradermics' oral minoxidil shows promise for hair regrowth, with some users reporting significant improvements, while Pelage's PP405 results are less convincing and lack transparency. There is skepticism about both treatments' long-term effectiveness and potential side effects.
community Most Promising Future Hair Loss Treatments In 2026
Promising hair loss treatments in 2026 include GT20029, a topical androgen receptor degrader, and VDPHL01, an extended-release oral minoxidil, both offering safer alternatives with fewer side effects. Other treatments like sublingual minoxidil, OND-1, JW0061, TDM-105795, and AMP-303 are also being explored.
community Pelage are starting phase 3 for PP405 towards the end of 2026
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
Related Research
6 / 6 results
research Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.
research Emerging pharmacotherapies for Androgenetic Alopecia
This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.
research Patient Profile and Treatment Characteristics of Adults and Adolescents Prescribed Ritlecitinib for Alopecia Areata in the USA
This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.
research Evaluating the Quality of TikTok Content on Alopecia: A Cross-Sectional DISCERN-Based Analysis
This study found that alopecia-related content on TikTok is generally low in quality, with dermatologist-created videos being higher quality but receiving less engagement compared to personal experience videos.
research The Intersection of Sleep and Hair Loss: A Systematic Review
This study suggests a possible bidirectional relationship between sleep quality and hair loss, indicating that addressing sleep disturbances might improve hair loss management and patient well-being.
research A Systematic Literature Review of Alopecia Areata in Children and Adolescents: Psychosocial Impact
This review highlights the significant psychosocial impact of alopecia areata on children and adolescents, affecting self-esteem, relationships, academic performance, and the well-being of their families.